A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Public ClinicalTrials.gov record NCT05329766. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)
Study identification
- NCT ID
- NCT05329766
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Enrollment
- 332 participants
Conditions and interventions
Conditions
Interventions
- Domvanalimab Drug
- Fluorouracil Drug
- Leucovorin Drug
- Oxaliplatin Drug
- Quemliclustat Drug
- Zimberelimab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 9, 2022
- Primary completion
- Dec 31, 2026
- Completion
- May 31, 2027
- Last update posted
- Apr 28, 2026
2022 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85054 | — |
| Research Site | Los Angeles | California | 90033 | — |
| Research Site | Santa Monica | California | 90024 | — |
| Research Site | Derby | Connecticut | 06418 | — |
| Research Site | Fort Myers | Florida | 33901 | — |
| Research Site | Jacksonville | Florida | 32224 | — |
| Research Site | St. Petersburg | Florida | 33705 | — |
| Research Site | Boston | Massachusetts | 02109 | — |
| Research Site | New York | New York | 10021-0005 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Columbus | Ohio | 43219 | — |
| Research Site | Oklahoma City | Oklahoma | 73104 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05329766, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 28, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05329766 live on ClinicalTrials.gov.